Cadila Healthcare is currently trading at Rs 748.00, up by 6.60 points or 0.89% from its previous closing of Rs 741.40 on the BSE.
The scrip opened at Rs 746.00 and has touched a high and low of Rs 754.25 and Rs 726.00 respectively. So far 9078 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 964.00 on 12-Sep-2012 and a 52 week low of Rs 681.00 on 23-Feb-2012.
Last one week high and low of the scrip stood at Rs 837.95 and Rs 721.00 respectively. The current market cap of the company is Rs 14987.59 crore.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.32% and 8.89% respectively.
Cadila Healthcare, also known as Zydus Cadila, an innovative global pharmaceutical company, has received the final approval from US Food Drug and Administrator (USFDA) to market Pioglitazone HC1 tablets in different strengths of 15mg, 30mg and 45mg. The drug falls in the anti-diabetics segment.The estimated sales in 2012 as per IMS for Pioglitazone HC1 tablets was $2 billion. Further, the group now has 75 approvals and has so far filed 170 ANDAs since the commencement of filing process in FY 2003-04.
Flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.00 |
Dr. Reddys Lab | 1351.00 |
Cipla | 1476.25 |
Lupin | 2170.00 |
Zydus Lifesciences | 973.65 |
View more.. |